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ABSTRACT
Off-label intravitreal use of the vascular endothelial growth factor (VEGF) antibody
bevacizumab for retinopathy of prematurity (ROP) increases despite lack of studies on
safety, pharmacokinetics and dosage in developing individuals. Systemic absorption has
been considered negligible. A literature search was performed with emphasis on potential
adverse systemic effects in developing individuals.
Conclusion: Intravitreal bevacizumab enters the general circulation, suppresses
plasma VEGF levels and remains in the blood for more than 8 weeks in primates. Possible
adverse effects on VEGF-dependent development must be considered.
INTRODUCTION
The number of publications on the off-label use of intravi-
treal bevacizumab (Avastin
 , Roche, Basel, Switzerland) for
severe retinopathy of prematurity (ROP) is rapidly increas-
ing. Although most authors agree that studies of pharmaco-
kinetics and systemic safety are needed, no such studies on
preterm infants have been published. A recent editorial
expressed the opinion that it seems reasonable to assume
that intravitreal bevacizumab is safe and that it should be
the treatment of choice for zone I ROP (1). Others question
the use of this medication without clinical trials with
meticulous evaluation of multiple variables that normally
precedes the introduction of drugs in clinical use (2,3).
One randomized controlled study of intravitreal use of
bevacizumab (BEAT-ROP) has been published so far (4).
The dose injected was 0.625 mg, i.e., half the dose used in
adults. Regarding safety, it was concluded that for assess-
ment of mortality, 2800 infants would be required and
Abbreviations
BPD, Bronchopulmonary dysplasia; HUVEC, Human umbilical
vein endothelial cell; IC50, Half maximal inhibitory concentra-
tion; NO, Nitric oxide; PDR, Proliferative diabetic retinopathy;
PMA, Postmenstrual age; rhuMab, Recombinant humanized
monoclonal antibody; ROP, Retinopathy of prematurity; VEGF,
Vascular endothelial growth factor.
Key notes
• Intravitreal bevacizumab enters the general circulation,
results in prolonged VEGF inhibition and has a half-life of
1–2 weeks in primates. VEGF is critical for growth and
development of vital organs such as kidneys, lungs and
brain during the third trimester. After proper investigations
of systemic effects, pharmacokinetics and dosage, anti-
VEGF might be an opportunity for severe ROP. As an alter-
native to laser, its effects are presently too poorly known.
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even larger number of infants. It was stated that bev-
acizumab could not escape the eye more than in very small
amounts because of its large size, unless laser therapy had
destroyed the retinal barrier.
A prematurely born infant receiving treatment for ROP is
at a stage when growth and differentiation normally are
intense. Early development is characterized by critical peri-
ods of susceptibility when environmental factors effectively
produce long-lasting changes. Knowing that vascular endo-
thelial growth factor (VEGF) is essential for normal angio-
genesis and, in addition, has neuroprotective effects, we set
outtoreviewstudiesonsafety,pharmacokineticsanddosage
of the drug in relation to the developmental stages of impor-
tantorgansduringthethirdtrimesterandearlypostnatallife.
Bevacizumab is a recombinant humanized vascular endo-
thelial VEGF antibody that prevents VEGF from binding to
its receptors (5). Bevacizumab binds to all isoforms of
VEGF (6), blocks VEGF-induced angiogenesis and is
approved by the U.S. Food and Drug administration for
intravenous use for metastatic colorectal cancer. It is used
off-label intravitreal to treat neovascular retinal disorders
such as age-related macular degeneration (7), diabetic reti-
nopathy (8) and central retinal vein occlusion (9).
Metabolism and elimination of bevacizumab are similar
to those of endogeneous IgG, i.e., primarily via proteolytic
catabolism in the whole body including endothelial cells
and not mainly through the kidneys or the liver (FASS.se).
Vascular endothelial growth factor, a secreted glycopro-
tein, is an angiogenic as well as a vasopermeable factor
which is secreted by foetal and adult epithelial and mesen-
chymal cells and exerts mitogenic effects on endothelial
cells. In the foetus, VEGF is expressed in most tissues. In
normal angiogenesis, VEGF activity often represents a rate-
limiting step. Median plasma concentrations of VEGF in
premature babies in one study showed a large variation but
no signiﬁcant difference between infants without and with
ROP at 32 weeks postmenstrual age (PMA) (median 0.
658 ng⁄mL, range 0.049–2.152 and median 0.904, range
0.142–2.349, respectively) and at 36 weeks PMA (median
0.437, range 0.089–2.367 and 0.344, range 0.066–
1.334 ng⁄mL, respectively) (10). In the human kidney,
VEGF is highly expressed during glomerular development
and also in the adult indicating roles for normal glomerulo-
genesis and for control of vascular permeability (11). A
strong dosage sensitivity for VEGF-A in the developing glo-
merulus has been reported, and dysregulation of VEGF has
been found to play a pathogenic role in glomerular disease.
A note of caution for clinical trials aimed at altering VEGF
levels has been issued and careful monitoring of renal func-
tion with a particular emphasis on the glomerular ﬁltration
barrier is recommended (12).
In the human lung, primitive alveoli are ﬁrst seen at PMA
29 weeks. With increasing gestation, the alveoli get thinner
walls, and at 36 weeks, all alveoli are thin walled (13).
There is strong evidence that VEGF is necessary for alveo-
larization during normal lung development and that inhibi-
tion of VEGF during a critical period of growth contributes
to bronchopulmonary dysplasia (BPD) (14). In a study of
premature mice, VEGF increased surfactant synthesis and
improved lung function and was considered a potential
therapeutic possibility for respiratory distress syndrome
(15).
In a study on human foetal and postnatal brains, VEGF
expression was found in different locations during different
time periods. Bevacizumab treatment for ROP mainly takes
place at PMA 30–40 weeks. At that time, VEGF expression
was found in some brain locations but not in others (16).
DOSAGE, PHARMACOKINETICS AND SAFETY
In vitro
In the following, all concentrations of VEGF and bev-
acizumab inblood will be expressed as ng⁄mL for simplicity.
Wang et al. (17) studied bevacizumab-induced inhibition
of VEGF (50 ng⁄mL)-mediated effects on human umbilical
vein endothelial cells (HUVECs) in cultures. They found a
dose-dependent inhibition of VEGF-induced HUVEC pro-
liferation with an estimated half maximal inhibitory concen-
tration (IC50)o f2 2n g ⁄mL. The addition of 500 ng⁄mL of
bevacizumab completely blocked VEGF-induced endothe-
lial cell growth, suggesting that a molar ratio of bev-
acizumab to VEGF of 2.6:1 is needed for maximum
inhibition. Also for blockage of HUVEC survival, nitric
oxide (NO) production and permeability, a ratio of 2.6:1
was efﬁcient, while a ratio of 10:1 was needed to block
migration.
Porchine VEGF binds to bevacizumab. In perfused organ
cultures from pig’s eyes, where 0.35 ng⁄mL of VEGF was
produced per hour, VEGF was completely neutralized for
16 h by 0.25 mg⁄mL of bevacizumab and 0.125 mg⁄mL of
ranibizumab. The efﬁciency of the two drugs was similar
(18).
Mice and rats
Mice and rat VEGF lack afﬁnity for bevacizumab (5), and
studies on effects of anti-VEGF treatment have been per-
formed using other methods. In newborn mice, partial inac-
tivation of VEGF led to increased mortality, impaired
general growth and growth of organs, especially the liver
(19) and in 24 days old mice to disturbed cartilage remodel-
ling (20).
Pharmacokinetic studies have shown that rhuMab VEGF
(=bevacizumab) was cleared from the serum in a biphasic
manner with an initial half-life of 1.2 h in mice and 7 h in
rats, and the terminal half-life was 1–2 weeks (5).
Two of the most common adverse effects seen in adults
receiving bevacizumab for cancer are proteinuria and
hypertension. In mice, local ongoing VEGF production of
podocytes in the kidney is necessary for the functioning of
the adult glomerular ﬁltration barrier and altered glomeru-
lar permeability appeared to be a direct consequence of
VEGF inhibition in one study (21).
In rats, serum concentrations of bevacizumab after intra-
vitreal injections were higher in animals with branch retinal
vein occlusion than in healthy animals (22), indicating that
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amounts of the drug to enter the general circulation.
Rabbits
Rabbits have a sparsely vascularized retinas and their VEGF
has reduced afﬁnity for bevacizumab, about a ﬁfth of that of
primates [Ferrari personal communication in (5)]. Using ra-
diolabelled rhuMab VEGF (=bevacizumab) intravenously
in rabbits (5), the distribution indifferent organs could be
studied. Radioactivity in plasma was found to be tenfold
higher than in tissues where the organs exhibiting the high-
est radioactivity concentration after 2 h in decreasing rank
order were kidney, testes, spleen, heart, lung and thymus
with lower levels in brain and eye.
A few pharmacokinetic studies of intravitreal bev-
acizumab have been performed in rabbits of which one
deals with newborn animals (23–25). In rabbit pups, who
received 1.25 mg of intravitreal bevacizumab 8 days previ-
ously, serum concentrations were signiﬁcantly higher in
2 weeks old animals (19 300 ng ± 8100 ng⁄mL) than in
6 weeks old animals (4400 ± 1300 ng⁄mL; Table 1) (23).
In male rabbits (1.7–2.0 kg), intravitreal injection of
1.25 mg bevacizumab in one eye resulted in a peak concen-
tration of 400 000 ng⁄mL in the vitreous after 1 day, con-
centration declined with a half-life of 4.32 days and
>10 000 ng⁄mL was maintained for 30 days (Table 1). In
serum, a maximum concentration of 3300 ng⁄mL was
found 8 days after injection and it declined with a half-life
of 6.86 days. In the vitreous of the fellow eye, bevacizumab
concentrations increased from 0.35 ng⁄mL day 1 to
11.17 ng⁄mL at 4 weeks (24).
In a study by Nomoto et al., intravitreal injection of
1.25 mg in one eye of rabbits weighing 1.9–2.5 kg each
resulted in a maximal concentration in plasma of
2087 ± 2008 ng⁄mL at 2 weeks with a half-life of
1.85 weeks (Table 1). In the fellow eyes, bevacizumab from
the systemic circulation resulted in concentrations in the
retina⁄choroid which were maintained above IC50 for
8.0 weeks (25).
In the eye, bevacizumab has been found to be tolerated
well (26,27), although a dose-dependent increase in apopto-
sis has been revealed in photoreceptors and other cells
(28,29). Full retinal thickness penetration was found 24 h
after injection of 2.5 mg but not after 4 weeks (27).
Nonhuman primates
Early pharmacokinetic studies of intravenous administra-
tion of rhuMab VEGF (=bevacizumab) in cynomolgus mon-
keys showed that the antibody was cleared from the serum
in a biphasic manner with an initial half-life of 11–26 h and
a terminal half-life of 1–2 weeks and that the terminal phase
was dominant (5).
Intravitreal injection of 1.25 mg bevacizumab in one eye
of three male adult cynomolgus macaques (3.9–5.5 kg)
resulted in maximum serum concentrations after 1 week of
1430 ± 186 ng⁄mL (Table 1). Reduction rate was low, and
at 8 weeks, serum concentrations were 67.1 ± 24.3 ng⁄mL,
which was approximately 187 times higher than that of the
aqueous humour of the treated eye. The effect on serum
VEGF concentrations could not be studied because they
were below the limit of detection (0.031.2 ng⁄mL) through-
out the experiment (Fig. 1) (30).
In another study on cynomolgus macaques, intravitreal
bevacizumab penetrated through the retina and was found
in choroidal vessels throughout the experiment indicating
substantial transfer of the drug to the blood circulation.
Enrichment of bevacizumab was found in rod photorecep-
tors and endothelial cells of blood vessels (31). In addition,
a reversible reduction in the number of choriocapillaris
endothelial cell fenestration has been found for at least
Table 1 Bevacizumab concentrations in different compartments after intravitreal injection in one eye
Species Weight (kg) Age (weeks) Dose (mg) Days after injection Compartment Bevacizumab concentration (ng⁄mL) References
Rabbit 1.7–2.0 1.25 1 Vitreous 400 000 24
30 Vitreous >10 000
8 Serum 3300
Rabbit 1.9–2.5 1.25 14 Plasma 2087 25
Rabbit (pup) ? 2 1.25 8 Serum 19 400 ± 8100 23
6 8 Serum 4400 ± 1300
Macaque 3.9–5.5 1.25 7 Serum 1430 ± 186 30
8 weeks Serum 67.1 ± 24.3
Figure 1 Bevacizumab concentrations in injected eye, uninjected eye and
serum after intravitreal injection of 1.25 mg in one eye of adult cynomolgus
macaques. From Miyake et al. (30) with the publisher‘s permission.
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as well as choriocapillaris perfusion disturbances (32).
Interestingly, a recent report demonstrates pronounced
sustained choroidal vascular involution during the develop-
ment of ROP (33).
Humans
In adults with proliferative diabetic retinopathy (PDR),
patients treated with intravitreal injection of 1.25 mg bev-
acizumab in one eye before vitrectomy had signiﬁcantly
lower serum VEGF 7 days after treatment (34). In another
study of adults with PDR, different doses (0.0062, 0.0125,
0.062, 0.125, 0.625 and 1.25 mg) of bevacizumab were
injected intravitreal, and consistent biologic effects were
noted at all doses. A possible therapeutic effect in fellow
eyes was found in single patients receiving 1.25 mg in one
eye, also indicating that systemic inhibitory concentrations
can be achieved in adults (8). We have found no studies of
bevacizumab or its effect on VEGF in serum or plasma in
preterm infants or in immature animals except the one on
rabbit pups by Wu et al. (23).
DISCUSSION
Bevacizumab enters the general circulation and stays there
for weeks to months. It also reaches the fellow eye in poten-
tially therapeutic concentrations (Fig. 1). Young age (23),
possibly due to smaller size, and impaired blood–retinal
barrier (22) increase serum concentrations. Intravitreal bev-
acizumab has been reported to reduce serum levels of
VEGF in adults (34).
In the cell culture study by Wang et al. (17), 500 ng⁄mL
of bevacizumab was able to neutralize 50 ng⁄mL of VEGF.
Vitreous VEGF levels in type I ROP are unknown, but in
vascularly active stage 4 ROP eyes, Sonmez et al. (35) found
median (range) concentrations of 3.454 (0.774–8.882)
ng⁄mL which were signiﬁcantly higher than 0.316 (0.105–
0.665) ng⁄mL in vascularly inactive stage four eyes and
0.059 (0.038–0.135) ng⁄mL in controls. In stage 5 ROP, lev-
els of 0.119 ± 0.66 ng⁄mL have been found (36). Bakri et al.
(24) found intravitreal bevacizumab concentrations of
400 000 ng⁄mL after 1 day and >10 000 ng⁄mL 30 days
after injection of 1.25 mg. If similar concentrations are
achieved in infant eyes, the doses currently used appear to
be very high. Avery et al. (8) found consistent effects on
PDR of intravitreal injection of doses as low as 0.006 mg of
bevacizumab.
In contrast to the adult healthy macaque, the preterm
infant with proliferative ROP has a compromised blood–
retinal barrier that may allow more bevacizumab to enter
the blood stream. Assuming that a preterm infant with type
I ROP at 30–36 weeks is about half the size of an adult
macaque of 3.9–5.5 kg and that the serum concentrations
reached after an intravitreal injection of 0.625 mg would be
similar or, more likely, higher than in the monkey receiving
1.25 mg, serum concentrations after 1 week would be
roughly 1400 ng⁄mL and after 8 weeks 70 ng⁄mL in the
baby (30). Systemic VEGF concentrations in preterm
infants show a large variation. Pieh et al. (10) found median
(range) plasma concentrations of 0.90 (0.14–2.35) ng⁄mL
and 0.34 (0.07–1.33) ng⁄mL at 32 and 36 week’s PMA,
respectively, in infants with ROP. One must, therefore, sus-
pect that serum bevacizumab levels 8 weeks after intravitre-
al injection still prevents VEGF from acting in preterm
infants at a stage when VEGF is needed for the develop-
ment of kidneys, lungs, brain and other organs.
Very preterm infants at risk for severe ROP have subnor-
mal functioning of many organ systems for the rest of their
lives. Anti-VEGF treatment may have the capacity to reduce
their reserves even further. These effects may not be obvious
until decades after treatment. For clinical off-label use of a
drug, basic research and animal experiments are required to
evaluate its safety and to reveal potential adverse effects. It
is important to note that, in most patients, type I ROP
regresses after laser, which has been used for many years
with proven efﬁcacy except in the most severe cases. The
effects of laser treatment are limited to the eye.
The antibody fragment ranibizumab (Lucentis
 , Novartis,
Basel, Switzerland), which has a shorter half-life in serum
in monkeys 3.5 days (37) than bevacizumab (12.3
± 2.6 days) (30) and was developed because of concerns of
systemic adverse effects of bevacizumab, may be an alterna-
tive to study further although 40-fold more expensive.
We suggest that:
1 Experimental studies on animal species with VEGF
that binds to bevacizumab (primates, pigs) at the
developmental stages corresponding to the human
third trimester regarding adverse effects on developing
organs such as kidneys, lungs and brain are performed.
2 Infants with very severe ROP who are treated with
bevacizumab after laser failure should be included in
controlled pharmacokinetic, dose⁄efﬁcacy and safety
trials with close monitoring of serum concentrations of
VEGF.
3 Until the above-mentioned studies have been per-
formed, infants who can be treated successfully with
laser should not receive anti-VEGF.
Full information about the lack of evidence for safety and
efﬁcacy should be given to parents before preterm infants
are treated with intravitreal bevacizumab.
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